shouldiuse.io

VERDICT

Should I use DealForma?

DealForma tracks biopharma licensing, venture, and M&A deal data in a modern interface. Relevant categories and deal comps to help you be more confident using quality data in your business development research. - dealforma.com

Depends. Buy if you're a biopharma BD, corp-dev, or investment team needing curated licensing, M&A, and venture comps. Skip if you work outside biopharma or can't absorb ~$18K/yr per seat.

Confidence

Medium. Based on 14 public sources; pricing partly truncated and mostly self-reported, so treat numbers as approximate.

Ratings

  • Value for money
  • Ease of use
  • Feature depth
  • Support quality
  • Security postureNo security page or disclosures found

Pricing

Individual

~$18,000/yr (listing truncated)

ModelNot disclosed
Monthly feesNot disclosed
HardwareNot disclosed

Best for

  • Biopharma BD teams
  • Big pharma corporate development
  • Biotech-focused VCs and bankers
  • Consultants running biotech DD

Not for

  • Anyone outside biopharma — zero coverage elsewhere
  • Solo researchers who can't justify ~$18K/yr
  • Teams needing broad private-company data (use PitchBook)
  • Buyers wanting self-serve trials and transparent pricing

Gotchas - check before you buy

medium

~$18K individual seat; team pricing likely quote-based — confirm costs before demo

medium

Small vendor ($550K reported revenue): key-person and support-depth risk

medium

Pricing is demo-gated; no self-serve trial evident

low

Guess: curated proprietary data may not export cleanly to rival tools

Pros and cons

Pros

  • Specialized biopharma coverage: licensing, M&A, venture, pipelines
  • Data cited by WSJ, J.P. Morgan, and Nature
  • Positions itself as focused alternative to PitchBook and Evaluate Pharma
  • Quarterly deal trend reports show ongoing data curation
  • Named biotech customer case studies available

Cons

  • Individual tier reportedly ~$18K/yr
  • Biopharma-only — no value outside life sciences
  • No public security page found
  • Thin independent review footprint; little third-party validation

Sources & method

Analyzed 9/21/2026 - 14 sources - No known vulnerabilities found in the sources reviewed.

official x6review x5security x1news x2

Key stats

  • Value for money: 2/5

    Rating

  • ~$18,000/yr (listing truncated)

    Starting price

  • 14

    Sources

  • Analyzed

  • Value for money: 2/5. Individual tier reportedly ~$18K/yr
  • Ease of use: 4/5. Positioned as intuitive alternative to PitchBook/Evaluate
  • Feature depth: 4/5. Deep biopharma deal data; cited by WSJ, JPM
  • Support quality: 3/5. Hands-on case studies, but vendor is tiny
  • Security posture. No security page or disclosures found
  • ~$18K/yr Starting price Individual tier, f6s listing
  • $550K Reported revenue GetLatka estimate
  • WSJ, J.P. Morgan, Nature Data cited by Public reports

Pricing

Individual

~$18,000/yr (listing truncated)

  • Subscription biopharma deal database
  • Licensing, M&A, venture deal data

Security

No known vulnerabilities found in the sources reviewed.

What users say

Independent reviews are scarce; third-party guides praise its curated biopharma focus and its own site shows strong customer testimonials.

“I absolutely love DealForma.”
DealForma homepage testimonial

Companies that use it

  • Pragma Bio11
  • J.P. Morgan⁹
Full analysis

Based on 14 public sources; pricing partly truncated and mostly self-reported, so treat numbers as approximate.

Credible biopharma-only deal database cited by WSJ and JPM; ~$18K/yr. Great for BD teams, useless outside biopharma.

Methodology

Based on 14 public sources; pricing partly truncated and mostly self-reported, so treat numbers as approximate.

Sources

  1. DealForma homepagedealforma.com
    official
  2. DealForma pricing pagedealforma.com
    official
  3. DealForma Platform Reviews and Pricing 2026 (f6s)f6s.com
    review
  4. DealForma vs Dynamic AI — GetLatkagetlatka.com
    review
  5. PitchBook Alternative — DealFormadealforma.com
    official
  6. Evaluate Pharma Alternative — DealFormadealforma.com
    official
  7. AlphaSense vs DealFormaalpha-sense.com
    review
  8. Ambrosia vs DealForma comparisoncalculator.ambrosiaventures.co
    review
  9. J.P. Morgan Biopharma and Medtech Deal Reports (powered by DealForma)jpmorgan.com
    news
  10. DealForma on X — WSJ citationx.com
    news
  11. DealForma case studiesdealforma.com
    official
  12. DealForma security pagedealforma.com
    security
  13. DealForma demo pagedealforma.com
    official
  14. Biopharma Deal Databases Compared — Ambrosia guideambrosiaventures.co
    review

Rate this review

Anonymous. You can change your vote.

Loading votes…

Comments

One queue. No nested comments. Give a display name first. Limit: 200 words per comment and 7 comments per day. You can edit or delete yours.

Save a name to write a comment.

0 / 200 words

No comments yet.